253 related articles for article (PubMed ID: 9679969)
1. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation.
Faessel HM; Slocum HK; Jackson RC; Boritzki TJ; Rustum YM; Nair MG; Greco WR
Cancer Res; 1998 Jul; 58(14):3036-50. PubMed ID: 9679969
[TBL] [Abstract][Full Text] [Related]
2. Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines.
Faessel HM; Slocum HK; Rustum YM; Greco WR
Biochem Pharmacol; 1999 Mar; 57(5):567-77. PubMed ID: 9952321
[TBL] [Abstract][Full Text] [Related]
3. Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.
Faessel HM; Slocum HK; Rustum YM; Greco WR
Int J Oncol; 2003 Aug; 23(2):401-9. PubMed ID: 12851689
[TBL] [Abstract][Full Text] [Related]
4. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
5. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
[TBL] [Abstract][Full Text] [Related]
7. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
8. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
9. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
[TBL] [Abstract][Full Text] [Related]
10. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
11. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of folic acid enhancement of antifolate synergism.
Gaumont Y; Kisliuk RL; Parsons JC; Greco WR
Cancer Res; 1992 Apr; 52(8):2228-35. PubMed ID: 1532766
[TBL] [Abstract][Full Text] [Related]
13. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of sensitivity and natural resistance to antifolates in a methylcholanthrene-induced rat sarcoma.
Li WW; Lin JT; Schweitzer BI; Bertino JR
Mol Pharmacol; 1991 Nov; 40(5):854-8. PubMed ID: 1719370
[TBL] [Abstract][Full Text] [Related]
15. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Backus HH; Pinedo HM; Wouters D; Padrón JM; Molders N; van Der Wilt CL; van Groeningen CJ; Jansen G; Peters GJ
Int J Cancer; 2000 Sep; 87(6):771-8. PubMed ID: 10956384
[TBL] [Abstract][Full Text] [Related]
16. Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells.
Seither RL; Trent DF; Mikulecky DC; Rape TJ; Goldman ID
J Biol Chem; 1989 Oct; 264(29):17016-23. PubMed ID: 2529254
[TBL] [Abstract][Full Text] [Related]
17. Effect of direct suppression of thymidylate synthase at the 5,10-methylenetetrahydrofolate binding site on the interconversion of tetrahydrofolate cofactors to dihydrofolate by antifolates. Influence of degree of dihydrofolate reductase inhibition.
Seither RL; Trent DF; Mikulecky DC; Rape TJ; Goldman ID
J Biol Chem; 1991 Mar; 266(7):4112-8. PubMed ID: 1825652
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
19. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression.
Mayer-Kuckuk P; Banerjee D; Malhotra S; Doubrovin M; Iwamoto M; Akhurst T; Balatoni J; Bornmann W; Finn R; Larson S; Fong Y; Gelovani Tjuvajev J; Blasberg R; Bertino JR
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3400-5. PubMed ID: 11891321
[TBL] [Abstract][Full Text] [Related]
20. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
